This is the first reported case of a patient with EGFR mutation in NSCLC who experienced rapid progression after 2‐month treatment with the targeted drug Osimertinib, resulting in multiple liver metastases and primary drug resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.